Pacira reports July 2022 net product sales of $50.2M; EXPAREL daily sales up 5% YoY

Pacira BioSciences, Inc.

2022-Q2 EPS reported $0.55 revenue$327,402,000

Preliminary unaudited net product sales for July 2022: $50.2M total ($40.9M EXPAREL, $8.2M ZILRETTA, $1.1M iovera°).
EXPAREL net sales flat vs. July 2021 at $40.9M, but average daily sales up 5% on 20 vs. 21 selling days.
ZILRETTA sales of $8.2M reflect continued early-stage growth; iovera° sales $1.1M vs. $1.0M prior year.
CEO cites expanding EXPAREL adoption; Phase 3 lower extremity nerve block results expected in Q3 and Q4 2022.
No FY2022 revenue or gross margin guidance provided due to ongoing COVID-19 and labor uncertainty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.